- Trials with a EudraCT protocol (20)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
20 result(s) found for: Suicide intervention.
Displaying page 1 of 1.
EudraCT Number: 2016-004422-42 | Sponsor Protocol Number: ESKETINSUI2002 | Start Date*: 2017-10-02 | ||||||||||||||||||||||||||
Sponsor Name:Janssen-Cilag International NV | ||||||||||||||||||||||||||||
Full Title: A Double-blind, Randomized, Psychoactive Placebo-controlled, Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in Addition to Comprehensiv... | ||||||||||||||||||||||||||||
Medical condition: Major Depressive Disorder with Imminent Risk of Suicide | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: HU (Completed) ES (Restarted) BE (Completed) PL (Completed) IT (Completed) BG (Completed) FR (Completed) Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-002905-24 | Sponsor Protocol Number: 74304 | Start Date*: 2021-07-07 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Efficacy and feasibility of intranasal ketamine on acute suicidality, a double blind randomized placebo-controlled trial (Ketamine Trial for Acute suicidalty, KETA) | ||
Medical condition: Acute suicidality, which is a rapid increase in suicidal ideation or behaviour from the patient's 'baseline' in the last 24 hours. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004291-18 | Sponsor Protocol Number: 54135419TRD4010 | Start Date*: 2021-04-08 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: Open-label Long-Term Extension Study for Participants With Treatment-Resistant Major Depressive Disorder Who are Continuing Esketamine Nasal Spray Treatment From Study 54135419TRD3013 | |||||||||||||
Medical condition: Treatment-Resistant Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) CZ (Completed) HU (Completed) PL (Completed) BG (Completed) FI (Completed) GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004334-42 | Sponsor Protocol Number: 31-08-252 | Start Date*: 2013-02-14 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients with Bipolar I Disorder | |||||||||||||
Medical condition: Bipolar I disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002939-18 | Sponsor Protocol Number: GWEP1447 | Start Date*: 2016-04-29 | |||||||||||
Sponsor Name:GW Research Ltd. | |||||||||||||
Full Title: A phase 2, double-blind, randomized, placebo-controlled pharmacokinetic trial in two parallel groups to investigate possible drug- drug interactions between stiripentol or valproate and GWP42003-P ... | |||||||||||||
Medical condition: Epilepsy | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) SE (Completed) NL (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000469-18 | Sponsor Protocol Number: IP2018CS01 | Start Date*: 2020-06-26 |
Sponsor Name:Initiator Pharma | ||
Full Title: A Randomised, Double-Blind, Placebo-Controlled, Crossover Trial Studying the Efficacy and Safety of IP2018 in Depressed, Erectile Dysfunction (ED) Patients | ||
Medical condition: Male patients with a diagnosis of mild to moderate depression and ED as determined from the Hamilton depression scale score of 7 to 23 and International Index of Erectile Function (IIEF-5) score of... | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002942-33 | Sponsor Protocol Number: GWEP1428 | Start Date*: 2015-10-27 | |||||||||||
Sponsor Name:GW Research Ltd | |||||||||||||
Full Title: A phase 2, double-blind, randomized, placebo-controlled study to investigate possible drug-drug interactions between clobazam and cannabidiol (GWP42003-P) | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002463-61 | Sponsor Protocol Number: JZP385-201 | Start Date*: 2022-03-28 | |||||||||||
Sponsor Name:Cavion, Inc., a subsidiary of Jazz Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2b, 12-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study of the Safety and Efficacy of JZP385 in the Treatment of Adults with Moderate to Severe Essentia... | |||||||||||||
Medical condition: Essential Tremor (ET) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003369-16 | Sponsor Protocol Number: GWAP19030 | Start Date*: 2020-06-02 |
Sponsor Name:GW Research Ltd. | ||
Full Title: A Randomized, Double-blind, Parallel-group Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants with Schizophrenia Experiencing Inadequate... | ||
Medical condition: Schizophrenia is neurodevelopmental syndrome, results from gradual alterations in brain connectivity. Can persist for years before psychosis emerges. Individuals have a 2 to 3 fold increased risk o... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-000942-21 | Sponsor Protocol Number: AIMS-2-CT1 | Start Date*: 2019-07-24 | |||||||||||||||||||||
Sponsor Name:Celso Arango | |||||||||||||||||||||||
Full Title: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents w... | |||||||||||||||||||||||
Medical condition: Autism Spectrum Disorder | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002947-27 | Sponsor Protocol Number: SIMCODE | Start Date*: 2020-01-22 |
Sponsor Name:Charité – Universitätsmedizin Berlin | ||
Full Title: Simvastatin add-on to Escitalopram in patients with comorbid obesity and major depression: A multicenter, randomized, double-blind, placebo-controlled trial | ||
Medical condition: Patients with comorbid obesity (body mass index ≥ 30) and major depression | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000567-77 | Sponsor Protocol Number: 42847922MDD1016 | Start Date*: 2021-05-19 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Short-term Exploratory Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have ... | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA ES (Prematurely Ended) IT (Prematurely Ended) SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005733-16 | Sponsor Protocol Number: DNLI-H-0001 | Start Date*: 2022-07-19 | |||||||||||
Sponsor Name:Denali Therapeutics Inc. | |||||||||||||
Full Title: A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in ... | |||||||||||||
Medical condition: Frontotemporal Dementia (FTD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Temporarily Halted) PT (Trial now transitioned) CZ (Completed) FR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001521-16 | Sponsor Protocol Number: 1VIT14037 | Start Date*: 2015-07-15 | |||||||||||
Sponsor Name:Luitpold Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Double-Blinded, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) in the Treatment of Restless Legs Syndrome (RLS) | |||||||||||||
Medical condition: Restless Leg Syndrome (RLS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) PL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004532-30 | Sponsor Protocol Number: R092670PSY3016 | Start Date*: 2019-08-09 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: Single-arm, Open-label Extension to a Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005451-32 | Sponsor Protocol Number: F17464GE201 | Start Date*: 2014-07-09 | |||||||||||
Sponsor Name:Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF) | |||||||||||||
Full Title: Effects of F17464 in acute exacerbation of schizophrenia. | |||||||||||||
Medical condition: schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) LV (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002868-17 | Sponsor Protocol Number: 633765 | Start Date*: 2016-05-06 | |||||||||||
Sponsor Name:Fundación Centro Nacional de Investigaciones Cardiovasculares, Carlos III (CNIC) | |||||||||||||
Full Title: Secondary Prevention of Cardiovascular Disease in the Elderly | |||||||||||||
Medical condition: Secondary Prevention of Major Cardiovascular Events (cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, and urgent revascularization) in post MI cohort. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) CZ (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004826-87 | Sponsor Protocol Number: NONSTOP | Start Date*: 2012-06-08 | |||||||||||||||||||||
Sponsor Name:Fundacion Progreso y Salud | |||||||||||||||||||||||
Full Title: Randomized multicentric open-label phase III clinical trial to evaluate the efficacy of continual treatment versus discontinuation based in the presence of prodromes in a first episode of non-affe... | |||||||||||||||||||||||
Medical condition: First-episodes of non-affective psychosis. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-000637-43 | Sponsor Protocol Number: CTH-301 | Start Date*: 2016-05-12 | |||||||||||
Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
Full Title: An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF... | |||||||||||||
Medical condition: "Levodopa Responsive Patients with Parkinson’s Disease complicated by Motor Fluctuations (“OFF” Episodes)" | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Ongoing) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001476-11 | Sponsor Protocol Number: AL002-2 | Start Date*: 2020-11-12 | |||||||||||
Sponsor Name:Alector Inc. | |||||||||||||
Full Title: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AL002 IN PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE | |||||||||||||
Medical condition: Early Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) PL (Completed) DE (Completed) IT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
